Benralizumab in EGPA: real-world effectiveness and safety

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

BELONG-EGPA is a multicenter, retro-prospective observational study at European EGPA Study Group centers, assessing benralizumab 30 mg every 4 weeks in adults with EGPA. Researchers will collect clinical, laboratory, and lung function data from medical charts at baseline and at 3, 6, 12, and 24 months to evaluate effectiveness and safety in routine care. Primary outcomes include complete or partial disease response, changes in pre-bronchodilator FEV1, and relapse rates, with response definitions based on BVAS and steroid use. Inclusion requires confirmed EGPA by current criteria or MIRRA criteria, age 18+, and at least 3 months of follow-up after starting treatment. Data will be gathered via standardized electronic case report forms across participating centers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years or older.
* Diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) according to the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria or the criteria proposed in the MIRRA trial.
* Treatment with benralizumab 30 mg every 4 weeks.
* At least 3 months of available follow-up data after starting benralizumab.
* Written informed consent for study participation and data collection.

Exclusion Criteria:

* Age younger than 18 years.
* No available follow-up data after starting benralizumab.
* Follow-up after benralizumab initiation shorter than 3 months.
* Lack of written informed consent, where required by local regulations.

Where it's running

• Edoardo Biancalana
  Florence, Italy, Italy Recruiting

Study contacts

• Principal investigator: Giacomo Emmi, MD/PhD — University of Trieste, Italy
• Study coordinator: Giacomo Emmi, MD/PhD
• Email: giacomo.emmi0105@gmail.com
• Phone: +393286852815

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Continued benralizumab for participants who completed a prior benralizumab study

  This trial tests continuing benralizumab in people who benefited from it in a previous study, to see if long-term treatment is safe and tolerable.

  Recruiting at 20 sites Phase 3 AstraZeneca · Aurora, Colorado and 45 other locations · NCT07444567

• Investigating benralizumab for children with eosinophilic diseases

  This study is testing if a medication called benralizumab can help children aged 6 to under 18 with eosinophilic granulomatosis with polyangiitis feel better and stay healthy over a year of treatment.

  Recruiting at 13 sites Phase 3 AstraZeneca · Aurora, Colorado and 14 other locations · NCT06512883

• Benralizumab treatment for adults with ABPA and severe asthma

  This will test whether benralizumab helps adults (18–75) who have severe asthma with allergic bronchopulmonary aspergillosis (ABPA).

  Recruiting at 2 sites Qianfoshan Hospital · Jinan, Shandong and 1 other locations · NCT07530770

• Real-world benralizumab treatment for adults with severe eosinophilic asthma in Italy

  This study will test whether benralizumab helps adults with severe eosinophilic asthma reach partial or complete clinical remission during routine care in Italy.

  Recruiting at 12 sites AstraZeneca · Salerno, Battipaglia and 27 other locations · NCT07214753

• Real-world use of benralizumab in Chinese patients with severe eosinophilic asthma

  See how benralizumab works for people in China aged 12 and up with severe eosinophilic asthma when given as part of routine care.

  Recruiting at 36 sites AstraZeneca · Anning and 35 other locations · NCT06862206

• Observational study on asthma control with benralizumab

  This study is testing how well benralizumab helps people with severe eosinophilic asthma manage their symptoms and improve their quality of life over a year.

  Recruiting at 40 sites AstraZeneca · Ahrensburg and 40 other locations · NCT06422078

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.